Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Stoke Therapeutics, Inc.NASDAQ: STOK
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$50M, compared with $112.88M a year earlier. Trailing-twelve-month net income was -$169.77M. Over 3 fiscal years it compounded at -59.2% a year.
Context
- Net income amounted to 3.7% of revenue in FY2025, down 239.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$231.33M (+3259.9%) for the fiscal year ending Dec 2026, a step up from the -92.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$50M-13.7% QoQ
- Last fiscal yearDec 2025
- -$6.89M-92.3% YoY
- LTMMar 2026
- -$169.77M-437.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (6.89M) USD
- Year-over-year change
- +92.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.89M) | +92.3% |
| FY2024 | 2024-12-31 | (88.98M) | +15.0% |
| FY2023 | 2023-12-31 | (104.7M) | -3.6% |
| FY2022 | 2022-12-31 | (101.07M) | -17.8% |
| FY2021 | 2021-12-31 | (85.81M) | — |
Net Income vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -437.7% is the lowest of 6, against a peer median of +51.2%.
- Net income amounts to 529.2% of revenue for STOK, versus a peer median of 255.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $546.15M USD | +113.1% | +12.2% | 56.9% | |
| LTM Mar 2026 | $183.59M USD | +63.4% | +8.1% | 255.7% | |
| LTM Mar 2026 | $169.77M USD | -437.7% | -59.2% | 529.2% | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Jun 2026 | $85.43M USD | -78.6% | -34.8% | 54.7% | |
| LTM Mar 2026 | $69.71M USD | +24.0% | +3.3% | — | |
| LTM Mar 2026 | €45.62M EUR | +51.2% | -14.2% | 339.4% | |
| Peer median (excluding STOK) | — | +51.2% | +5.7% | 255.7% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| Deferred Income Tax | 172K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.45M | 22.85M | 25.26M | 27.47M | 32.24M |
| Change in Working Capital | 46K | 43.02M | (6.03M) | (28.14M) | 16.35M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (4.27M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.9M | 121K | (3.21M) | 3.09M | 21.29M |
| Other Working Capital | (2.85M) | 42.9M | (2.82M) | (31.23M) | (675K) |
| Other Non-Cash Items | 1.26M | 1.78M | 1.94M | 623K | 2.12M |
| Operating Cash Flow | (66.91M) | (31.87M) | (81.07M) | (86.85M) | 45.59M |
| Capital Expenditures | (1.2M) | (3.96M) | (1.62M) | (203K) | (670K) |
| Acquisitions (Net) | 75.23M | 45.34M | 0 | 0 | 0 |
| Purchases of Investments | (87.23M) | (201.32M) | 0 | (167.27M) | (322.72M) |
| Sales of Investments | 12M | 159.4M | 107.56M | 60M | 136.58M |
| Other Investing Activities | (75.23M) | (45.34M) | 0 | 0 | 0 |
| Investing Cash Flow | (76.43M) | (45.88M) | 105.95M | (107.48M) | (186.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.29M | 45.34M | 52.08M | 128.84M | 97.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | 1.07M | 926K | 2.25M | 0 |
| Financing Cash Flow | 1.28M | 46.41M | 53.01M | 131.09M | 97.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (142.05M) | (31.34M) | 77.89M | (63.23M) | (43.84M) |
| Free Cash Flow | (68.11M) | (35.83M) | (82.68M) | (87.05M) | 44.92M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.